Welcome To The Resverlogix HUB On AGORACOM
**Apabetalone (RVX-208) Currently Being Tested in a Phase 3 BETonMACE Cardiovascular Outcomes Trial and a Phase 2a Kidney Dialysis Trial**
AGORACOM NEWS FLASH
MUST WATCH INTERVIEWS THIS WEEK!
INTERVIEW: Missed the AGM? You’re In Luck - HPQ Goes Beyond The AGM – June 23, 2017
----------------------------------------------------
INTERVIEW: Harry Barr Discusses Canada's Largest Primary PGM Deposit + Lithium Initiatives
Due Dilligence
Resverlogix: The Science Is Getting 'BETter' For RVX208
Posted by:
BearDownAZ
on
Feb 27, 2017 11:49AM
Resverlogix Corp. Links
Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)
Paper published in Journal of Cardiovascular Translational Research on May 31, 2017
Posted by:
BearDownAZ
on
Jun 01, 2017 01:52PM
Bloom Burton & Co. Healthcare Investor Conference Slides
Posted by:
BearDownAZ
on
May 02, 2017 11:08AM
Zacks SCR Report 3/27/2017
Price Target Up; More BETonMACE Sites Opening
Posted by:
BearDownAZ
on
Mar 27, 2017 06:04PM
Resverlogix Cowen Conference 3/8/17 slides
Resverlogix presented at Cowen and Company 37th Annual Health Care Conference on 3/8/17
Posted by:
BearDownAZ
on
Mar 08, 2017 03:43PM
Resverlogix: The Science Is Getting 'BETter' For RVX208
Posted by:
BearDownAZ
on
Feb 27, 2017 11:49AM
Resverlogix BIO CEO & Investor Conference 2/14/17 Slides
Posted by:
BearDownAZ
on
Feb 14, 2017 02:00PM